Venture Life Dividends - VLG

Venture Life Dividends - VLG

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Venture Life Group Plc VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change Price Change % Stock Price Low Price High Price Open Price Close Price Last Trade
-1.75 -2.57% 66.25 66.25 68.00 68.00 68.00 09:00:22
more quote information »
Industry Sector

Venture Life VLG Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount

Top Dividend Posts

redartbmud: An interesting argument is developing. Is there something new to be found in the arguments? Markets trive on argument and counter argument, buys and sells. Different camps - growth investing, value investing, dividend investing, buying tne dogs of the prrviuos year etc etc. Question: If we could analyse all of the recommendations issued by the tintins, since the beginning of the latest turmoil, would the ratios of buys v sells be significantly different in today's markets? Their job is to help create a market in the shares on which they comment. Logic told us to sell at the beginning of the episode, and buy back at much lower prices. When is that point? There are exceptions to that rule, and for those shares, you would now be out of pocket. The income argument has largely gone out of the window. I am convinced that dividends will be rebased more closely to prevailing cash interest rates. It will still generate a premium, for the risk of holding an investment that 'could go down as well as up'. As I see it, little has changed, when applying fundamentals. 1. Don't invest in companies with flat or declining profit streams, whose balance sheet is stuffed with debt. Most of the income is used to cover interest payments, and that may account for all or most of the free cash flow. A small dip in profits has a disproportionately negative multiplier effect, and destroys any perceived value in the business. 2. Seek out quality. The key is finding growth in vibrant sectors of the market. One where management is hungry for success, but not reckless it it's pursuit. 3. Companies that you can understand. 4. Recognise disruptors that can flourish - the Boos and Fevers of this world. They have been preceded by a long line of successful businesses, such a Rsw and Spx, but in a different time, and a different sector. 5. Throw away the conventions - maybe things like 'sell half on a doub;e' etc. There has always been an argument to run the winners, and add along the way. 6. Be ruthless, when the story changes to the negative. Most of the time, the share price falls, and it may take years to recover. Don't be afraid to take losses. The reamining cash can be reinvested more profitably elsewhere. How long must I wait for Equals to actually produce something positive? Just a ew things to consider. Please add to the debate. Now is a good time for re-evaluation. red
redartbmud: H You can have the best of both worlds. A mix of boring stable companies, that generate good regular dividend growth, and modest share price growth, coupled with some growth businesses that return above average capital gains. Using the income from the Gsk, Rdsb(pre-covid global meltdown) to invest in the then tiddlers, like Spx and Rsw has proved to be a good balance, over the years. BTFD on mispricing of shares is a fun element. Each to his own. red
redartbmud: If dividends are pegged to bank base rates and therefore payouts more modest, it does create additional free cash flow for investment in the business. wisely spent, it should increase year on year returns in the form of growth and a higher share price. How many CEO's are capable? The principle remains unchanged. Put your money on the nose of the horse with the sheepskin noseband. red
apad: Agree with the Adam/red debate. Terry Smith has to do it with 'brand' megacaps. We can do it with the likes of BREE. A huge advantage. HLMA is a great example of the argument - it can always find better things to do with cash than pay large divis. But they do increase the divi year on year, so doing nothing also works if one doesn't need the income. Strange how the BOO discourse changed after the last results, Hydrus. The big issue for me is that PLT is not stealing BooHoo's customers - now shown over a couple of results. BOO is now 26% of Stairway. I've traded a few times and the net cost is 55p. The story hasn't changed through all the share price variations and I have no reason to want to reduce this proportion. apad
redartbmud: Adam Absolutely. I have a large holding in Breedon. They have been in growth mode, and payment of a dividend has not been on the agenda. I have traded a few annually, mainly to generate a 'dividend' which I have taken as a 'scrip', adding to my holding. If you are going to adopt this policy, for the big caps, you need to consider the levels of growth in the business, and it's size. Yes, the shares are liquid, but the larger holders will find it difficult to trade sufficient numbers to generate equivalent dividend income, where the shares trade in a relatively tight range for a relatively long period. This could happen to the companies which have been more bond proxies, pottering along serenely on a calm ocean, never making waves. Not all businesses can grow at 4, 5 or 6% annually to create that 'dividend' opportunity. The holders would all be in the same boat, and if they all try to jump at the same time, they just depress the share price, defeating the object. PI's may have a better chance, but why trade in the backwater that will only provide a few crumbs, where other tables offer much greater opportunities. If they underperform, against market expectations, the share price declines further, resukting in a capital loss that far outweighs any 'dividend' trade. red
penpont: Here's the ST comment: Venture Life huge Chinese sales agreement Aim-traded Venture Life (VLG:59.5p), a developer, manufacturer and distributor of products for the self-care market, has announced its largest ever contract award, an exclusive 15-year agreement worth €168m (£147m) with its existing Chinese distribution partner. This is the minimum amount the partner needs to purchase to retain its exclusive distribution rights in China, Macau and Hong Kong for Venture’s Dentyl brand (mouthwashes, toothpastes, tooth whiteners and fresh breath beads) and some other products. Since the start of 2020, Venture has received orders of €7m from the distribution partner after demand surged on the back of a new marketing initiative (funded by the partner), both before and after the outbreak of Covid-19. Analysts at Cenkos Securities estimate that the single agreement has a net present value of £21m (15p a share) based on a maintained gross margin of 40 per cent, additional operating costs being borne by the Chinese partner, and after applying a discount rate of 12.4 per cent to the cash flows generated. That’s a material sum in relation to the £4.2m Venture paid for the Dentyl brand in 2018, and the company’s market capitalisation of £52m. It also means that Venture will start each year with a contracted order book of £10m from this agreement alone. There are not many companies that could double profits in 2020, but Venture is one of them. Even before the latest contract win, the order book was 2.5 times higher than at the same stage last year, and that excludes a contribution from the acquisition of PharmaSource, a distributor of a range of medical device products (fungal nail infections, wart removal and women's health). To put Venture’s top-line growth into perspective, Cenkos expects 2020 revenues to increase by a quarter to £25.3m. So, with gross margins being maintained on a relatively fixed cost base, earnings per share (EPS) should almost double to 4.3p as operational leverage kicks in. Venture’s strong trading performance has not gone unnoticed. Last week, the share price hit the 66p target price I outlined in my May 2019 Alpha Report, delivering a 46 per cent return during which time theFTSE Aim All-Share index has shed 16 per cent of its value. The Chinese distribution agreement has added further value, and de-risked the investment case, too. On a cash-adjusted 2020 forward PE ratio of 12.5, my new target price is 75p. Buy.
investorschampion: The share price soared 26% on the contract news, but at 63p trades at only 15x adjusted earnings per share for the year ending March 2020, with the current market capitalisation of £53m equivalent to just over 2x 2020 forecast revenues. Read more in our daily update on the impact of the coronavirus on VLG and other stocks we follow here: hxxps://
rivaldo: Wow - a minimum EUR168m purchase commitment over 15 years for Dentyl and other products from China :o)) VLG's largest ever contract win (by miles I'd have thought!) will give great security going forward for sales to China, Macau, Hong Kong and Taiwan: Https://
redartbmud: XPD It looks like we still have a functioninh business. Wonder if the share price will wake up, just a bit. 2019 Highlights Strong revenue growth combined with good cash generation · Substantial increase in revenues by 19.0% to £213.2 million · Like for like revenues increased by 10.4% reflecting good organic growth · Delivered ahead of revised expectations with adjusted profit before tax of £5.2m1 · Improved cash generation with a strong focus on working capital · Maintained financial headroom with positive net cash (excluding liabilities arising from the impact of right-of-use assets debt) of £7.0 million, as at 31 December 2019 · Adjusted earnings per share decreased by 41.7% to 2.80p · Final proposed scrip dividend, with the intention to return to cash dividends from the 2020 half year results. EPS ????? red
rivaldo: Nice summary - here's a link that works: Https:// "Venture Life: miraculously gets an upgrade Consumer self-care group Venture Life Group (LON: VLG) has issued a very positive trading update moving the broker to upgrade forecasts. All its business units in the UK, Italy and the Netherlands remain operational with stringent precautions in place to protect employees and comply with government rulings. The group’s Italian business is still allowed to operate as it is considered an essential business. The group has received orders of over €7m from its Chinese partner (compared to only €0.5m total sales in 2019) for Dentyl and other products, for delivery in 2020. As part of the effort to combat coronavirus, Venture Life is manufacturing hand sanitiser gel at its facility in North Lombardy, which it is supplying free of charge to local hospitals and pharmacies. In recognition of the positive news the house broker upgraded forecasts for the year ending December 2020, a highly unusual outcome in the current environment. Forecast adjusted earnings per share of 4.3p equates to a very modest price earnings multiple of 7.8x at the current share price of 33p, which rose 30% on the day."
ADVFN Advertorial
Your Recent History
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200525 21:06:06